ES2507091T3 - Nanofiltración de soluciones del factor VII para eliminar virus - Google Patents

Nanofiltración de soluciones del factor VII para eliminar virus Download PDF

Info

Publication number
ES2507091T3
ES2507091T3 ES04804635.3T ES04804635T ES2507091T3 ES 2507091 T3 ES2507091 T3 ES 2507091T3 ES 04804635 T ES04804635 T ES 04804635T ES 2507091 T3 ES2507091 T3 ES 2507091T3
Authority
ES
Spain
Prior art keywords
factor vii
nanofiltration
polypeptides
eliminate viruses
solutions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04804635.3T
Other languages
English (en)
Spanish (es)
Inventor
Jesper Christensen
Erik Halkjaer
Turid Preuss
Thomas Budde Hansen
Lene Vaedele Madsen Tomoda
Nina Johansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Original Assignee
Novo Nordisk Health Care AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34639198&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2507091(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Health Care AG filed Critical Novo Nordisk Health Care AG
Application granted granted Critical
Publication of ES2507091T3 publication Critical patent/ES2507091T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES04804635.3T 2003-12-01 2004-12-01 Nanofiltración de soluciones del factor VII para eliminar virus Expired - Lifetime ES2507091T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK200301775 2003-12-01
DKPA200301775 2003-12-01
PCT/EP2004/053206 WO2005054275A2 (en) 2003-12-01 2004-12-01 Nanofiltration of factor vii solutions to remove virus

Publications (1)

Publication Number Publication Date
ES2507091T3 true ES2507091T3 (es) 2014-10-14

Family

ID=34639198

Family Applications (2)

Application Number Title Priority Date Filing Date
ES04804635.3T Expired - Lifetime ES2507091T3 (es) 2003-12-01 2004-12-01 Nanofiltración de soluciones del factor VII para eliminar virus
ES19186952T Expired - Lifetime ES2926359T3 (es) 2003-12-01 2004-12-01 Filtración de virus de composiciones líquidas del Factor VII

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19186952T Expired - Lifetime ES2926359T3 (es) 2003-12-01 2004-12-01 Filtración de virus de composiciones líquidas del Factor VII

Country Status (14)

Country Link
US (8) US20070142625A1 (enExample)
EP (3) EP1711513B1 (enExample)
JP (3) JP4874806B2 (enExample)
KR (1) KR101234170B1 (enExample)
CN (3) CN1890257A (enExample)
AU (1) AU2004294403A1 (enExample)
BR (1) BRPI0416950B8 (enExample)
CA (1) CA2545474A1 (enExample)
DK (1) DK1711513T3 (enExample)
ES (2) ES2507091T3 (enExample)
PL (1) PL1711513T3 (enExample)
PT (1) PT1711513E (enExample)
RU (1) RU2472804C2 (enExample)
WO (1) WO2005054275A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1711513T3 (pl) * 2003-12-01 2014-12-31 Novo Nordisk Healthcare Ag Nanofiltracja roztworów czynnika vii w celu usunięcia wirusów
DE102005037824A1 (de) * 2005-08-08 2007-02-15 Zlb Behring Gmbh Neuartiges Virusreduktionsverfahren
PH12013501365A1 (en) 2010-12-30 2013-09-16 Laboratoire Francais Du Fractionnment Et Des Biotechnologies Glycols as pathogen inactivating agents
MX2013010737A (es) 2011-03-25 2014-03-12 Genentech Inc Novedosos metodos de purificacion de proteinas.
MY195362A (en) 2012-06-21 2023-01-16 Baxalta Inc Virus Filtration of Cell Culture Media
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
RU2526494C1 (ru) * 2013-03-19 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) Способ удаления вируса иммунодефицита человека из спермы мужчины
PL3068417T3 (pl) * 2013-11-15 2024-05-13 F.Hoffmann-La Roche Ag Sposoby inaktywacji wirusów przy użyciu ekologicznych detergentów
CN105435644A (zh) * 2014-09-29 2016-03-30 中国石油化工股份有限公司 一种纳滤膜及其制备方法
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100501A (en) 1960-12-23 1963-08-13 Crane Co Removable head and seat ball valve construction
JPS6033009B2 (ja) * 1978-12-29 1985-07-31 三菱電機株式会社 マイクロ波発振装置
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
JP3459416B2 (ja) 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5677162A (en) * 1995-05-01 1997-10-14 New York Blood Center, Inc. Method for activating prothrombin to thrombin
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
EP0860444A1 (en) * 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
AT407159B (de) * 1997-06-13 2001-01-25 Immuno Ag Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5981254A (en) 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
CA2308610A1 (en) 1997-11-05 1999-05-14 Welfide Corporation Heparin cofactor ii preparation and process therefor
FI106465B (fi) 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
WO2001004287A1 (en) 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
AU2001254624A1 (en) 2000-05-03 2001-11-12 Novo-Nordisk A/S Human coagulation factor vii variants
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
EP1319067A2 (en) 2000-09-13 2003-06-18 Novo Nordisk A/S Human coagulation factor vii variants
AU2001291653A1 (en) * 2000-10-02 2002-04-15 Novo-Nordisk A/S Industrial-scale serum-free production of recombinant factor vii in mammalian cells
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
JP4537059B2 (ja) 2001-09-27 2010-09-01 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
ES2561985T3 (es) 2001-10-10 2016-03-01 Ratiopharm Gmbh Remodelación y glicoconjugación de anticuerpos
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
US20050131005A1 (en) 2002-04-30 2005-06-16 Jiabing Wang 4-azasteroid derivatives as androgen receptor modulators
PL373728A1 (en) 2002-04-30 2005-09-05 Maxygen Holdings Ltd. Factor vii or viia polypeptide variants
WO2004011023A1 (de) 2002-07-23 2004-02-05 Bio-Products & Bio-Engineering Aktiengesellschaft Thrombingenerierfähige und thrombinhältige pharmazeutische wirkstoffzubereitungen und arzneimittel
RS20050051A (sr) 2002-07-23 2007-06-04 Bio-Products & Bio Engineering Ag., Farmaceutski aktivni sastojak preparata i medikamenata koji sadrže trombin ili imaju mogućnost stvaranja trombina
ATE505487T1 (de) 2002-09-30 2011-04-15 Bayer Healthcare Llc Fvii- oder fviia-varianten mit erhöhter koagulationswirkung
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
PL1711513T3 (pl) 2003-12-01 2014-12-31 Novo Nordisk Healthcare Ag Nanofiltracja roztworów czynnika vii w celu usunięcia wirusów
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII

Also Published As

Publication number Publication date
CN1890257A (zh) 2007-01-03
BRPI0416950A8 (pt) 2019-01-22
DK1711513T3 (da) 2014-09-15
JP2012021007A (ja) 2012-02-02
JP5666359B2 (ja) 2015-02-12
US20170022482A1 (en) 2017-01-26
BRPI0416950A (pt) 2007-02-13
PT1711513E (pt) 2014-10-02
ES2926359T3 (es) 2022-10-25
EP1711513A2 (en) 2006-10-18
US20220064605A1 (en) 2022-03-03
CA2545474A1 (en) 2005-06-16
CN102351953A (zh) 2012-02-15
US20120115204A1 (en) 2012-05-10
JP2011173889A (ja) 2011-09-08
US20070142625A1 (en) 2007-06-21
BRPI0416950B8 (pt) 2021-05-25
US20200248150A1 (en) 2020-08-06
US9102762B2 (en) 2015-08-11
US20190032026A1 (en) 2019-01-31
JP4874806B2 (ja) 2012-02-15
EP3594222A1 (en) 2020-01-15
CN102351953B (zh) 2017-05-10
US20080274534A1 (en) 2008-11-06
US20150299685A1 (en) 2015-10-22
JP2007537994A (ja) 2007-12-27
EP1711513B1 (en) 2014-07-02
EP3594222B1 (en) 2022-08-03
EP2275432A1 (en) 2011-01-19
RU2472804C2 (ru) 2013-01-20
AU2004294403A1 (en) 2005-06-16
CN106916802A (zh) 2017-07-04
RU2006118024A (ru) 2008-01-10
WO2005054275A2 (en) 2005-06-16
CN106916802B (zh) 2022-03-25
KR101234170B1 (ko) 2013-02-18
PL1711513T3 (pl) 2014-12-31
KR20070001887A (ko) 2007-01-04
WO2005054275A3 (en) 2005-09-09
BRPI0416950B1 (pt) 2019-05-28

Similar Documents

Publication Publication Date Title
ES2507091T3 (es) Nanofiltración de soluciones del factor VII para eliminar virus
ES2504175T3 (es) Composición limpiadora de superficies duras ácida y líquida
ES2600737T3 (es) Absorción de líquidos por materiales estructurales organometálicos
ES2527423T3 (es) Método de eliminación de dióxido de azufre de una corriente de gas de combustión
ES2596880T3 (es) Composición para el análisis de glicoproteínas
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
ES2092228T3 (es) Nueva membrana de fibras huecas de alto flujo.
ES2542853T3 (es) Método para tratar miastenia grave
BRPI0516682A (pt) meio de filtração e processo para filtrar matéria particulada
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
ES2629089T3 (es) Utilización de 2,6-Di-terc-butil-p-cresol para el aumento de la estabilidad en almacenamiento de biodiésel
JP2008500279A5 (enExample)
AR044748A1 (es) Cartucho y metodo para la preparacion de bebidas
AR052595A1 (es) Procesamiento a alta presion de composiciones bioactivas
CL2010000102A1 (es) Aparato de purificación que comprende una fuente de agua y sal y una membrana hidrofilica de elastómero de copoliester que permite pasar agua a través de ella como vapor y es capaz de evitar la sal desde la fuente de agua al pasar a través de la membrana hidrofilica. (div. sol 231-99).
RU2008136191A (ru) Лечение рака мочевого пузыря с использованием ео9 и пропиленгликоля
AR072441A1 (es) Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacion de los mismos
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
ES2526912T3 (es) Composición farmacéutica que contiene neurotoxina botulínica A2
PE20030298A1 (es) Filtros de agua y procesos para la utilizacion de los mismos
ES2651027T3 (es) Retirada de azufre usando absorbente de carbonato ferroso
BRPI0400375B8 (pt) processo para remover vírus em soluções de fibrinogênio para aplicação terapêutica
ES2507094T3 (es) Proteína específica del timo
ES2562347T3 (es) Dispositivo de proyección de chorros de agua mediante una placa perforada curvada
ES2657048T3 (es) Composición para la utilización en el tratamiento local de afecciones bucofaríngeas que comprende ibuprofeno o ketoprofeno